Molecular Mechanisms Regulated by FOXM1 in Chronic Lung Remodeling
FOXM1在慢性肺重塑中调控的分子机制
基本信息
- 批准号:10407550
- 负责人:
- 金额:$ 55.93万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-06-01 至 2023-03-03
- 项目状态:已结题
- 来源:
- 关键词:AblationAcuteAcute Lung InjuryAllergensAlveolarAlveolar MacrophagesAnimalsAntibodiesApplications GrantsCCL2 geneCell CountCell Differentiation processCell physiologyCellsChronicChronic Obstructive Pulmonary DiseaseDataEmbryoEpidermal Growth Factor ReceptorEpithelial CellsEvaluationExposure toFOXM1 geneFlow CytometryGenesGeneticGenetic TranscriptionGoblet CellsHistologicHistologyHouse Dust Mite AllergensHumanIn VitroInflammationInflammation MediatorsInflammatoryInterleukin-13Knockout MiceLasersLungMAP Kinase GeneMUC5AC geneMatrix MetalloproteinasesMechanicsMetaplastic CellMethylcholanthreneModelingMolecularMolecular TargetMucinousMucous body substanceMusMyeloid CellsPathogenesisPathway interactionsPatientsPeptide HydrolasesPharmacologyProductionProteinsPulmonary EmphysemaPulmonary InflammationRattusRespiratory physiologyRoleSTAT3 geneSignal PathwaySmokingTestingTransgenesTransgenic OrganismsTreatment EfficacyType II Epithelial Receptor CellUbiquitinationairway epitheliumairway remodelingalveolar epitheliumalveolar type II cellasthma modelcell typechemokinechronic respiratory diseasecigarette smokeefficacy evaluationexperimental studyexposure to cigarette smokeforkhead proteingain of functiongenetic approachhigh throughput screeningimprovedin vivoinfluenza infectioninhibitorloss of functionlung carcinogenesismacrophagemonocytemouse geneticsmulticatalytic endopeptidase complexnoveloverexpressionpreventrecruitresponsesmall moleculetherapeutic evaluationtherapeutic targettherapy outcometranscription factortranscriptome sequencing
项目摘要
PROJECT SUMMARY. COPD is a severe chronic respiratory disease, which is associated with smoking and
characterized by chronic lung inflammation, emphysema, airway remodeling and goblet cell metaplasia.
Identification of new molecular targets is needed to improve therapeutic outcomes in COPD patients. Our grant
application will explore the role of Forkhead transcription factor FOXM1 as a potential therapeutic target in
mouse and rat COPD models. FOXM1 is an embryonic transcription factor, which is not expressed in
quiescent lungs but aberrantly induced during lung carcinogenesis. We provide preliminary data demonstrating
that FOXM1 is activated in airway epithelial cells, macrophages and type II cells of COPD patients and mice
exposed to cigarette smoke (CS). Increased expression of FOXM1 in mouse and human lungs is associated
with emphysema and goblet cell metaplasia. Transgenic overexpression of FOXM1 in alveolar type II cells
exacerbated lung inflammation, leading to emphysema. Genetic deletion of Foxm1 gene from myeloid cells,
including macrophages and monocytes, decreased pulmonary inflammation after acute lung injury. Genetic
ablation of Foxm1 from airway club cells decreased goblet cell metaplasia caused by house dust mite
allergens. While FOXM1 is increased in human COPD and mouse genetic data suggest that FOXM1 is critical
goblet cell metaplasia, pulmonary inflammation and alveolar remodeling, molecular mechanisms regulated by
FOXM1 in COPD remain unknown. We propose to test the hypothesis that FOXM1 increases goblet cell
metaplasia and emphysema in COPD by transcriptionally activating distinct sets of pro-inflammatory and
mucinous genes in alveolar type II cells, airway club cells and macrophages. We will also test the therapeutic
efficacy of novel FOXM1 inhibitor RCM-1 in mouse and rat COPD models. Chronic CS exposure and a
combination of CS and Influenza infection will be used to induce pulmonary inflammation, emphysema and
goblet cell metaplasia. In Aim 1, we will identify molecular mechanisms regulated by FOXM1 in alveolar type II
cells (Aim 1A) and macrophages (Aim 1B) using purified cells and mice with specific ablation of Foxm1 gene
from these cell types. FOXM1 targets will be validated using de-identified human COPD lungs. In Aim 2A, we
will use mice with specific deletion of Foxm1 from airway club cells, to identify FOXM1 target genes critical for
differentiation of club cells into goblet cells in COPD model. In Aim 2B, we will test therapeutic potential of
novel, non-toxic FOXM1-inhibiting small molecule compound, RCM-1, which has been recently discovered in
my lab using a high throughput screen. Altogether, these studies will identify novel molecular mechanisms
critical for COPD pathogenesis and test therapeutic potential of FOXM1 inhibitors in animal COPD models.
项目摘要。COPD是一种严重的慢性呼吸道疾病,与吸烟和
其特征在于慢性肺部炎症、肺气肿、气道重塑和杯状细胞化生。
需要鉴定新的分子靶点以改善COPD患者的治疗结果。我们的资助
应用将探索叉头转录因子FOXM 1作为潜在治疗靶点的作用,
小鼠和大鼠COPD模型。FOXM 1是一种胚胎转录因子,在胚胎发育中不表达。
静止的肺,但在肺癌发生过程中异常诱导。我们提供的初步数据表明,
FOXM 1在COPD患者和小鼠的气道上皮细胞、巨噬细胞和II型细胞中被激活,
香烟烟雾(CS)。小鼠和人肺中FOXM 1表达增加与
肺气肿和杯状细胞化生肺泡II型细胞中FOXM 1的转基因过表达
加剧了肺部炎症导致肺气肿骨髓细胞中Foxm 1基因的遗传缺失,
包括巨噬细胞和单核细胞,减少急性肺损伤后的肺部炎症。遗传
去除气道俱乐部细胞Foxm 1减少屋尘螨引起的杯状细胞化生
过敏原虽然FOXM 1在人类COPD中增加,但小鼠遗传数据表明FOXM 1是至关重要的。
杯状细胞化生,肺部炎症和肺泡重塑,
FOXM 1在COPD中的作用尚不清楚。我们建议测试FOXM 1增加杯状细胞的假设,
通过转录激活不同的促炎性和
肺泡II型细胞、气道俱乐部细胞和巨噬细胞中的粘液基因。我们还将测试
新型FOXM 1抑制剂RCM-1在小鼠和大鼠COPD模型中功效。慢性CS暴露和
CS和流感病毒感染的组合将用于诱导肺部炎症、肺气肿和
杯状细胞化生在目标1中,我们将确定II型肺泡中FOXM 1调节的分子机制
细胞(Aim 1A)和巨噬细胞(Aim 1B),使用纯化的细胞和小鼠特异性切除Foxm 1基因
这些细胞类型。FOXM 1靶标将使用去识别的人COPD肺进行验证。在目标2A中,我们
将使用从气道俱乐部细胞中特异性缺失Foxm 1的小鼠,以鉴定FOXM 1靶基因,
COPD模型中棒状细胞向杯状细胞的分化。在目标2B中,我们将测试
一种新的、无毒的FOXM 1抑制小分子化合物,RCM-1,最近在
我的实验室用的是高通量筛选。总之,这些研究将确定新的分子机制,
关键的COPD发病机制和测试FOXM 1抑制剂在动物COPD模型中的治疗潜力。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Vladimir Kalinichenko其他文献
Vladimir Kalinichenko的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Vladimir Kalinichenko', 18)}}的其他基金
Molecular Mechanisms Regulated by FOXM1 in Chronic Lung Remodeling
FOXM1在慢性肺重塑中调控的分子机制
- 批准号:
10891764 - 财政年份:2023
- 资助金额:
$ 55.93万 - 项目类别:
Molecular Mechanisms Regulated by FOXM1 in Chronic Lung Remodeling
FOXM1在慢性肺重塑中调控的分子机制
- 批准号:
10055005 - 财政年份:2020
- 资助金额:
$ 55.93万 - 项目类别:
Molecular Mechanisms Regulated by FOXM1 in Chronic Lung Remodeling
FOXM1在慢性肺重塑中调控的分子机制
- 批准号:
10170416 - 财政年份:2020
- 资助金额:
$ 55.93万 - 项目类别:
Transcriptional Regulation of Endothelial Cells after Acute Lung Injury
急性肺损伤后内皮细胞的转录调控
- 批准号:
9900064 - 财政年份:2018
- 资助金额:
$ 55.93万 - 项目类别:
Transcriptional Regulation of Endothelial Cells after Neonatal Lung Injury
新生儿肺损伤后内皮细胞的转录调控
- 批准号:
10661242 - 财政年份:2018
- 资助金额:
$ 55.93万 - 项目类别:
Transcriptional regulation of goblet cell metaplasia
杯状细胞化生的转录调控
- 批准号:
8744367 - 财政年份:2014
- 资助金额:
$ 55.93万 - 项目类别:
Transcriptional regulation of goblet cell metaplasia
杯状细胞化生的转录调控
- 批准号:
9279216 - 财政年份:2014
- 资助金额:
$ 55.93万 - 项目类别:
Foxf1 Transcription Factor in Development of Pulmonary Capillaries
Foxf1转录因子在肺毛细血管发育中的作用
- 批准号:
9065597 - 财政年份:2006
- 资助金额:
$ 55.93万 - 项目类别:
Fox Transcription Factors in Development of Pulmonary Capillaries
肺毛细血管发育中的 Fox 转录因子
- 批准号:
7414733 - 财政年份:2006
- 资助金额:
$ 55.93万 - 项目类别:
Foxf1 Transcription Factor in Development of Pulmonary Capillaries
Foxf1转录因子在肺毛细血管发育中的作用
- 批准号:
8242633 - 财政年份:2006
- 资助金额:
$ 55.93万 - 项目类别:
相似海外基金
Combinatorial cytokine-coated macrophages for targeted immunomodulation in acute lung injury
组合细胞因子包被的巨噬细胞用于急性肺损伤的靶向免疫调节
- 批准号:
10648387 - 财政年份:2023
- 资助金额:
$ 55.93万 - 项目类别:
Lung epithelial cell-derived C3 in acute lung injury
肺上皮细胞衍生的 C3 在急性肺损伤中的作用
- 批准号:
10720687 - 财政年份:2023
- 资助金额:
$ 55.93万 - 项目类别:
Examining the role of TRMT1 and tRNA methylation in acute lung injury and ARDS
检查 TRMT1 和 tRNA 甲基化在急性肺损伤和 ARDS 中的作用
- 批准号:
10719249 - 财政年份:2023
- 资助金额:
$ 55.93万 - 项目类别:
Inducible HMGB1 antagonist for viral-induced acute lung injury.
诱导型 HMGB1 拮抗剂,用于治疗病毒引起的急性肺损伤。
- 批准号:
10591804 - 财政年份:2023
- 资助金额:
$ 55.93万 - 项目类别:
MAP2K1 AND MAP2K2 IN ACUTE LUNG INJURY AND RESOLUTION
MAP2K1 和 MAP2K2 在急性肺损伤中的作用及缓解
- 批准号:
10741574 - 财政年份:2023
- 资助金额:
$ 55.93万 - 项目类别:
Development of a new treatment for COVID-19-related acute lung injury targeting the microbiota-derived peptide corisin
针对微生物群衍生肽 corisin 开发治疗 COVID-19 相关急性肺损伤的新疗法
- 批准号:
23K07651 - 财政年份:2023
- 资助金额:
$ 55.93万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Probing immunovascular mechanobiology in pneumonia-associated acute lung injury at the single capillary level
在单毛细血管水平探讨肺炎相关急性肺损伤的免疫血管力学生物学
- 批准号:
10679944 - 财政年份:2023
- 资助金额:
$ 55.93万 - 项目类别:
The amyloid precursor protein protects against acute lung injury
淀粉样前体蛋白可预防急性肺损伤
- 批准号:
10575258 - 财政年份:2023
- 资助金额:
$ 55.93万 - 项目类别:
Role of macrophages and miRNA in regulating lung macrophage polarization and lung pathogenesis during respiratory virus-induced acute lung injury in normal and diabetic Syrian hamsters.
正常和糖尿病叙利亚仓鼠呼吸道病毒引起的急性肺损伤期间巨噬细胞和 miRNA 在调节肺巨噬细胞极化和肺部发病机制中的作用。
- 批准号:
10701207 - 财政年份:2023
- 资助金额:
$ 55.93万 - 项目类别:
Identification of novel phenotypes of acute lung injury using multimodal longitudinal data
使用多模态纵向数据识别急性肺损伤的新表型
- 批准号:
MR/Y000404/1 - 财政年份:2023
- 资助金额:
$ 55.93万 - 项目类别:
Fellowship